Provectus Biopharma Files 2024 10-K
Ticker: PVCT · Form: 10-K · Filed: Mar 28, 2025 · CIK: 315545
| Field | Detail |
|---|---|
| Company | Provectus Biopharmaceuticals, Inc. (PVCT) |
| Form Type | 10-K |
| Filed Date | Mar 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, financials
TL;DR
Provectus Biopharma dropped its 2024 10-K. Check financials for Series D preferred stock.
AI Summary
Provectus Biopharmaceuticals, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, incorporated in Delaware and headquartered in Knoxville, TN, operates in the pharmaceutical preparations sector. This filing covers its financial performance and business operations for the period, including details on its Series D Convertible Preferred Stock and Series D-One Convertible Preferred Stock.
Why It Matters
This 10-K filing provides investors and stakeholders with a comprehensive overview of Provectus Biopharmaceuticals' financial health and strategic direction for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Provectus faces inherent risks related to drug development, regulatory approvals, and market competition, which are detailed in its 10-K filing.
Key Numbers
- 2024-12-31 — Fiscal Year End (The period covered by the 10-K filing.)
- 2025-03-28 — Filing Date (The date the 10-K was submitted to the SEC.)
Key Players & Entities
- PROVECTUS BIOPHARMACEUTICALS, INC. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-28 (date) — Filing date
- Knoxville, TN (location) — Company headquarters and mailing address
- Series D Convertible Preferred Stock (security) — Mentioned in financial reporting
- Series D-One Convertible Preferred Stock (security) — Mentioned in financial reporting
FAQ
What is the primary business of Provectus Biopharmaceuticals, Inc.?
Provectus Biopharmaceuticals, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its SIC code [2834].
When is the fiscal year end for Provectus Biopharmaceuticals, Inc.?
The fiscal year end for Provectus Biopharmaceuticals, Inc. is December 31, as stated in the filing.
What is the SEC file number for this 10-K filing?
The SEC file number for this 10-K filing is 001-36457.
What types of preferred stock are specifically mentioned in the filing data?
The filing data specifically mentions PVCT:SeriesDConvertiblePreferredStockMember and PVCT:SeriesDOneConvertiblePreferredStockMember.
Where is Provectus Biopharmaceuticals, Inc. headquartered?
Provectus Biopharmaceuticals, Inc. is headquartered in Knoxville, TN, with its business and mailing addresses listed at 800 S. GAY STREET, SUITE 1610.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 28, 2025 regarding PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).